Literature DB >> 17133622

Evaluation of an on-target sample preparation system for matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in conjunction with normal-flow peptide high-performance liquid chromatography for peptide mass fingerprint analyses.

Mark E McComb1, David H Perlman, Hua Huang, Catherine E Costello.   

Abstract

Large-scale mass spectrometry (MS)-based proteomic analyses require high-throughput sample preparation techniques due to the increasing numbers of samples that make up a typical proteomics experiment. Moreover, extensive sample pre-treatment steps are necessary prior to MS acquisition for even the most rapid and robust MS-based proteomics methodology, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS followed by peptide mass fingerprinting (PMF) analysis. These include sample purification and fractionation, removal of digestion buffers or solvents, and spotting of sample with matrix onto the MALDI target. These multiple steps of time-consuming sample handling can result in high overall analysis costs and the likelihood of sample contamination and loss. In order to overcome some of these limitations in sample processing, we have investigated the use of a novel, simple, inexpensive 96-well elastomeric array that affixes to a MALDI target to create an on-target 96-well plate that accommodates a high solution volume (ca. 200 microL), thereby enabling the on-target processing of samples for MALDI-TOFMS. We explored several factors that influence MALDI sample preparation: type of matrix, solution volume, solution organic composition, solution drying rates and matrix/analyte co-crystallization methods. We also investigated the use of the 96-well elastomeric device for coupling MALDI-TOFMS analysis directly to high flow rate (1 mL/min) reversed-phase (rp)-HPLC. By developing an optimized, robust sample preparation protocol, we were able to obtain mass spectra with a high signal-to-noise ratio from peptide standards present at the 50-fmol level in large starting volumes of solution. PMF analyses were possible from 1-pmol and 500-fmol protein-digest standards. Coupling the device to high-flow HPLC (750 microL/min) yielded a robust and semi-automated means to obtain enhanced MALDI-TOFMS data at 500 ng of protein digest. These methodologies developed for this simple, on-target, elastomeric device show promise for streamlining the sample preparation process from HPLC to MALDI-MS. Copyright (c) 2006 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2007        PMID: 17133622     DOI: 10.1002/rcm.2805

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  4 in total

1.  Comparative proteomic analysis of serum diagnosis patterns of sputum smear-positive pulmonary tuberculosis based on magnetic bead separation and mass spectrometry analysis.

Authors:  Jiyan Liu; Tingting Jiang; Feng Jiang; Dandan Xu; Liliang Wei; Chong Wang; Zhongliang Chen; Xing Zhang; Jicheng Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays.

Authors:  Meital Cohen; Rami Yossef; Tamir Erez; Aleksandra Kugel; Michael Welt; Mark M Karpasas; Jonathan Bones; Pauline M Rudd; Julien Taieb; Herve Boissin; Dror Harats; Karin Noy; Yoram Tekoah; Rachel G Lichtenstein; Eitan Rubin; Angel Porgador
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

3.  A novel "reactomics" approach for cancer diagnostics.

Authors:  Sofiya Kolusheva; Rami Yossef; Aleksandra Kugel; Nirit Hanin-Avraham; Meital Cohen; Eitan Rubin; Angel Porgador
Journal:  Sensors (Basel)       Date:  2012-05-02       Impact factor: 3.576

4.  Diagnostic and prognostic role of serum protein peak at 6449 m/z in gastric adenocarcinoma based on mass spectrometry.

Authors:  Dongjian Song; Lifang Yue; Hao Li; Junjie Zhang; Zechen Yan; Yingzhong Fan; Heying Yang; Qiuliang Liu; Da Zhang; Ziqiang Xia; Pan Qin; Jia Jia; Ming Yue; Jiekai Yu; Shu Zheng; Fuquan Yang; Jiaxiang Wang
Journal:  Br J Cancer       Date:  2016-03-22       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.